BC
ENGN icon

Boxer Capital’s enGene Therapeutics ENGN Stock Holding History

Boxer Capital’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-727,900
Closed -$4.8M – 15
2024
Q3 		$4.8M Hold
727,900
– – 0.24% 54
2024
Q2 		$6.86M Hold
727,900
– – 0.36% 47
2024
Q1 		$12.3M Buy
+727,900
New +$8.91M 0.61% 39

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Boxer Capital's ENGN Position: Q4 2024 in Review

Boxer Capital sold out of enGene Therapeutics (ENGN) in Q4 2024, closing a stake of 727,900 shares — an estimated $4.8M sold.

Boxer Capital first reported a position in ENGN in Q1 2024 and held it in 3 quarters. The position peaked at $12.3M in Q1 2024. 34 funds tracked by Wall St. Rank hold ENGN as of Q4 2024.

  • Boxer Capital reported no remaining enGene Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Boxer Capital sold 727,900 enGene Therapeutics shares in Q4 2024, an estimated $4.8M.
  • Boxer Capital first reported a position in enGene Therapeutics in Q1 2024 and held it in 3 quarters.
  • Boxer Capital's enGene Therapeutics position peaked at $12.3M in Q1 2024.
  • 34 funds tracked by Wall St. Rank held enGene Therapeutics as of Q4 2024.

Based on Boxer Capital's 13F filing for Q4 2024.